▟ Vinebot intrinsic value, daily

← back

ILMN Illumina, Inc.

pharma · valued with opus low conviction · deep-dived 2026-10-26

SELL
Intrinsic value$111.44
Price (at call)$269.42
Margin of safety -58.6%
vs market (rating basis) -24.9%

A real consumables franchise, but $269 assumes growth Illumina has not shown since 2021.

The story

Illumina is still the dominant short-read sequencing platform. Its moat is the large installed base, locked-in consumables revenue (the razor/blade model) and workflow standards in clinical genomics. After the GRAIL write-offs and spin-off, and a few years of flat-to-down revenue hurt by China export restrictions, academic funding pressure and repricing to NovaSeq X, it is a mature franchise trying to restart growth through clinical oncology, multiomics and proteomics. The share price assumes that restart succeeds and that margins return to pre-GRAIL levels of about 30% or more.

I credit growth reaccelerating to 7% as clinical demand and the multiomics push offset weakness in China and academic budgets, and margins returning to the high-20s/low-30s Illumina earned before GRAIL. I don't assume the mid-30s peak returns because Element, Ultima, PacBio and MGI keep pressure on pricing. The 12-year horizon reflects a real consumables moat. Sales-to-capital is set above the reported 0.93 because that figure is inflated by acquired goodwill, and organic reinvestment needs are lighter. Even with these generous drivers my value probably stays well below $269, so the market is pricing in a growth runway I can't yet support.

Value drivers

Revenue growth (Y1)7.0%
Terminal growth3.5%
Forecast horizon12y
Target operating margin31.0%
Years to target margin5
Sales-to-capital1.50
Beta1.05
Failure probability2.0%
Cost of capital (WACC)9.5%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF8.60B
PV of terminal value9.14B
Equity value16.83B
÷ shares → per share$111.44

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.70B 7.0% 27.3% 1.01B 205.01M 800.27M 730.86M
2 5.01B 6.7% 28.2% 1.11B 209.39M 899.13M 749.92M
3 5.33B 6.4% 29.2% 1.22B 212.74M 1.00B 765.28M
4 5.66B 6.0% 30.1% 1.33B 214.96M 1.12B 776.85M
5 5.98B 5.7% 31.0% 1.45B 215.96M 1.24B 784.62M
6 6.30B 5.4% 31.0% 1.53B 215.65M 1.31B 762.29M
7 6.62B 5.1% 31.0% 1.61B 213.94M 1.39B 738.34M
8 6.94B 4.8% 31.0% 1.68B 210.78M 1.47B 712.95M
9 7.25B 4.5% 31.0% 1.76B 206.12M 1.55B 686.33M
10 7.55B 4.1% 31.0% 1.83B 199.92M 1.63B 658.67M
11 7.84B 3.8% 31.0% 1.90B 192.17M 1.71B 630.18M
12 8.11B 3.5% 31.0% 1.97B 182.89M 1.79B 601.06M

Key risks

  • Low-cost sequencing competitors (Element, Ultima, MGI/Complete Genomics) erode consumable pricing and share
  • China export restrictions and the unreliable entity listing permanently shrink a former growth market
  • NIH and academic funding cuts depress instrument placements and pull-through

Catalysts

  • Clinical oncology and genetic disease testing volumes driving higher consumables pull-through per NovaSeq X
  • Multiomics and proteomics launches opening an incremental market beyond sequencing

History

DatePriceIntrinsicMoSRating
2026-10-26$269.42 $111.44 -58.6% SELL
2026-09-22$238.82 $60.73 -74.6% SELL